Table 2.

Meta-analysis of included studies.

Characteristic	No. of patients	No. of studies	SEN	SPE	PPV	NPV	ACC
Sample size
<100	639	9	0.58 (95% CI 0.53–0.63)	0.83 (95% CI 0.79–0.87)	0.79	0.70	0.90 (95% CI 0.87–0.94)
≥100	821	4	0.66 (95% CI 0.62–0.69)	0.72 (95% CI 0.69–0.75)	0.70	0.68	0.87 (95% CI 84–90)
Study design
Pros	402	5	0.77 (95% CI 0.71–0.82)	0.99 (95% CI 0.99–0.100)	0.89	0.76	0.90 (95% CI 0.86–0.93)
Retro	1058	8	0.64 (95% CI 0.61–0.67)	0.71 (95% CI 0.68–0.73)	0.69	0.66	0.89 (95% CI 0.86–0.93)
SUVmax cut off value
≤2.5	965	9	0.64% (95% CI 0.59–0.69)	0.87% (95% CI 0.83–0.90)	0.73	0.64	0.92 (95% CI 0.90–0.95)
>2.5	498	4	0.65% (95% CI 0.62–0.68)	0.71% (95% CI 0.68–0.74)	0.73	0.71	0.77 (95% CI 0.72–0.82)
All
—	1460	13	0.65 (95% CI 0.63–0.68)	0.75 (95% CI 0.73–0.78)	0.73	0.69	89% (95% CI 0.86–0.91)